InsiderTrades.com logo
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
From American Alternative   |   Ad
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...
CLICK HERE TO GET YOUR GUIDE NOW
Samuel C. Blackman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Samuel Blackman Biography and Net Worth

Insider of Day One Biopharmaceuticals
Sam Blackman, co-founder and Chief Medical Officer of Day One, is a physician-scientist trained in pediatric hematology/oncology and neuro-oncology, and has led the early clinical development of more than 10 novel cancer therapeutics. Prior to founding Day One, Dr. Blackman was Head of Clinical Development at Mavupharma, where he led the advancement of a novel immunotherapeutic towards Phase 1 clinical trials. Prior to Mavupharma he was Head of Clinical Development at Silverback Therapeutics. Prior to Silverback, Dr. Blackman held roles of increasing responsibility at Juno Therapeutics, Seattle Genetics, Merck, and GlaxoSmithKline. Dr. Blackman was responsible for the pediatric development of dabrafenib, resulting in the first industry-sponsored pediatric oncology “basket trial”. Through roles at CureSearch and ACCELERATE, Dr. Blackman is an active leader in the pediatric oncology drug development community.   

Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his MD and PhD degrees from the University of Illinois at Chicago.

What is Samuel C. Blackman's net worth?

The estimated net worth of Samuel C. Blackman is at least $18.03 million as of April 18th, 2024. Dr. Blackman owns 1,174,662 shares of Day One Biopharmaceuticals stock worth more than $18,031,062 as of April 24th. This net worth approximation does not reflect any other investments that Dr. Blackman may own. Additionally, Dr. Blackman receives a salary of $651,000.00 as Insider at Day One Biopharmaceuticals. Learn More about Samuel C. Blackman's net worth.

How old is Samuel C. Blackman?

Dr. Blackman is currently 55 years old. There are 4 older executives and no younger executives at Day One Biopharmaceuticals. The oldest executive at Day One Biopharmaceuticals is Mr. Adam Dubow, General Counsel, who is 57 years old. Learn More on Samuel C. Blackman's age.

What is Samuel C. Blackman's salary?

As the Insider of Day One Biopharmaceuticals, Inc., Dr. Blackman earns $651,000.00 per year. There are 2 executives that earn more than Dr. Blackman. The highest earning executive at Day One Biopharmaceuticals is Dr. Jeremy Bender M.B.A., Ph.D., CEO, President & Director, who commands a salary of $900,000.00 per year. Learn More on Samuel C. Blackman's salary.

How do I contact Samuel C. Blackman?

The corporate mailing address for Dr. Blackman and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at [email protected]. Learn More on Samuel C. Blackman's contact information.

Has Samuel C. Blackman been buying or selling shares of Day One Biopharmaceuticals?

Within the last three months, Samuel C. Blackman has sold $160,200.00 in Day One Biopharmaceuticals stock. Most recently, Samuel C. Blackman sold 10,000 shares of the business's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $16.02, for a transaction totalling $160,200.00. Following the completion of the sale, the insider now directly owns 1,174,662 shares of the company's stock, valued at $18,818,085.24. Learn More on Samuel C. Blackman's trading history.

Who are Day One Biopharmaceuticals' active insiders?

Day One Biopharmaceuticals' insider roster includes Samuel Blackman (Insider), and Papanek Grant (Director). Learn More on Day One Biopharmaceuticals' active insiders.

Are insiders buying or selling shares of Day One Biopharmaceuticals?

During the last twelve months, Day One Biopharmaceuticals insiders bought shares 2 times. They purchased a total of 1,153,630 shares worth more than $13,867,054.00. During the last twelve months, insiders at the sold shares 18 times. They sold a total of 76,432 shares worth more than $1,146,612.98. The most recent insider tranaction occured on April, 18th when insider Samuel C Blackman sold 10,000 shares worth more than $160,200.00. Insiders at Day One Biopharmaceuticals own 8.4% of the company. Learn More about insider trades at Day One Biopharmaceuticals.

Information on this page was last updated on 4/18/2024.

Samuel C. Blackman Insider Trading History at Day One Biopharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2024Sell10,000$16.02$160,200.001,174,662View SEC Filing Icon  
3/25/2024Sell10,000$16.01$160,100.001,184,662View SEC Filing Icon  
2/27/2024Sell20,000$16.11$322,200.001,224,662View SEC Filing Icon  
2/16/2024Sell2,258$15.25$34,434.501,244,662View SEC Filing Icon  
11/16/2023Sell709$11.69$8,288.211,238,234View SEC Filing Icon  
8/17/2023Sell668$13.86$9,258.481,236,319View SEC Filing Icon  
6/5/2023Sell1,229$16.00$19,664.001,234,363View SEC Filing Icon  
5/16/2023Sell692$13.12$9,079.041,235,592View SEC Filing Icon  
3/10/2023Sell10,000$18.05$180,500.001,233,660View SEC Filing Icon  
2/16/2023Sell674$19.57$13,190.181,243,660View SEC Filing Icon  
2/10/2023Sell10,000$20.07$200,700.001,241,710View SEC Filing Icon  
1/10/2023Sell10,000$22.86$228,600.001,250,148View SEC Filing Icon  
12/1/2022Sell10,000$21.45$214,500.001,260,148View SEC Filing Icon  
11/16/2022Sell377$21.46$8,090.421,270,148View SEC Filing Icon  
8/16/2022Sell941$24.31$22,875.711,299,338View SEC Filing Icon  
8/1/2022Sell10,000$16.88$168,800.001,296,718View SEC Filing Icon  
7/1/2022Sell10,000$18.72$187,200.001,306,718View SEC Filing Icon  
6/15/2022Sell50,000$16.26$813,000.001,316,718View SEC Filing Icon  
1/3/2022Sell10,000$17.10$171,000.00View SEC Filing Icon  
12/1/2021Sell10,000$17.22$172,200.00View SEC Filing Icon  
See Full Table

Samuel C. Blackman Buying and Selling Activity at Day One Biopharmaceuticals

This chart shows Samuel C Blackman's buying and selling at Day One Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Day One Biopharmaceuticals Company Overview

Day One Biopharmaceuticals logo
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $15.19
Low: $14.97
High: $16.75

50 Day Range

MA: $15.28
Low: $13.77
High: $17.46

2 Week Range

Now: $15.19
Low: $9.67
High: $17.85

Volume

4,619,425 shs

Average Volume

772,543 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
From American Alternative   |   Ad
The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...
CLICK HERE TO GET YOUR GUIDE NOW